CytoMed (GDTC) 10% Owner Choo Chee Kong Buys 200,000 Shares

What Happened

• Choo Chee Kong, a reported 10% owner of CytoMed Therapeutics Ltd (GDTC), acquired a total of 200,000 shares in two open-market purchases: 100,000 shares on 2026-07-14 and 100,000 shares on 2026-07-20, each at $1.50 per share, for a combined cost of $300,000. The filing is an amendment (Form 4/A) correcting the transaction indicator to show these were acquisitions (not dispositions).

Key Details

• Transaction dates and prices: 2026-07-14 — 100,000 shares @ $1.50 ($150,000); 2026-07-20 — 100,000 shares @ $1.50 ($150,000).
• Total acquired: 200,000 shares for $300,000.
• Shares owned after transaction: Not specified in the summary provided; see the amended Form 4 for post-transaction beneficial ownership.
• Filing note: This is an amended Form 4 filed July 24, 2026 (accession 0001493152-26-034654). Footnote F1 states the amendment corrects the acquisition/disposition indicator from "D" (disposition) to "A" (acquisition); no other changes were made.
• No options, awards, gifts, or tax-withholding reported in the transactions shown.

Context

• As a 10% owner, Choo’s purchases increase an already substantial stake; purchases by large insiders can be taken as a stronger signal than routine executive sales, but filings alone don’t reveal motivation. This amendment only corrects the transaction type and does not change the underlying trades. Retail investors should review the full amended Form 4 for complete holdings and consult other company disclosures before drawing investment conclusions.